Adding Pembrolizumab to Chemo Improves Survival in Endometrial Cancer

TUESDAY, April 4, 2023 (HealthDay News) -- The addition of pembrolizumab to paclitaxel plus carboplatin is associated with longer progression-free survival for patients with advanced or recurrent endometrial cancer, according to a study published online March 27 in the New England Journal of Medicine.
Ramez N. Eskander, M.D., from the University of California at San Diego, and colleagues conducted a phase 3 trial involving 816 patients with measurable disease (stage III or IVA) or stage IVB or recurrent endometrial cancer to receive pembrolizumab or placebo (1:1 ratio) in addition to combination therapy with paclitaxel plus carboplatin in six cycles every three weeks followed by up to 14 maintenance cycles every six weeks. Patients were stratified according to mismatch repair-deficient (dMMR) or mismatch repair-proficient (pMMR) disease.
The researchers found that in the 12-month analysis, estimates of progression-free survival were 74 and 38 percent in the pembrolizumab and placebo groups, respectively, in the dMMR cohort (hazard ratio for progression or death, 0.30). Median progression-free survival was 13.1 and 8.7 months with pembrolizumab and placebo, respectively, in the pMMR cohort (hazard ratio, 0.54). For pembrolizumab and combination chemotherapy, adverse events were as expected.
"Pembrolizumab in combination with chemotherapy and continued as maintenance therapy led to significantly longer progression-free survival than placebo in patients with dMMR and pMMR endometrial cancers," the authors write.
Several authors disclosed financial ties to pharmaceutical companies, including Merck, the manufacturer of pembrolizumab.
Abstract/Full Text (subscription or payment may be required)
Related Posts
Early-Life Day Care Tied to Worsening Behavior in Kids
TUESDAY, March 15, 2022 (HealthDay News) -- The more time kids spend in day...
Health Improves Over Two Years for COVID-19 Hospitalization Survivors
THURSDAY, May 12, 2022 (HealthDay News) -- Survivors of COVID-19 hospitalization...
Coordinador de COVID de la Casa Blanca: los adultos de a partir de 60 años se deben poner un segundo refuerzo
LUNES, 18 de abril de 2022 (HealthDay News) -- Los estadounidenses de a partir...
Una reducción incluso ‘modesta’ en la función renal podría perjudicar a los adultos jóvenes, según un estudio
VIERNES, 23 de junio de 2023 (HealthDay News) -- Los adultos jóvenes que tienen...